-

09:36:55 AM

Last DCPH Stock Market News

DCPH - Deciphera Pharmaceuticals Inc

05/04/21 4:22 PM

Nasdaq : DCPH

Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2021, and provided a corporate update."We are excited by the continuing successful commercial launch of QINLOCK in the U.S. as we solidify its position among GIST prescribers and

RHEA-AI

positive

04/27/21 7:00 AM

Nasdaq : DCPH

Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021.In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, May 4,

RHEA-AI

neutral

03/02/21 7:00 AM

Nasdaq : DCPH

Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 9, 2021 at 1:50 PM ET. The conference will be held in a virtual meeting format.A live

RHEA-AI

neutral

02/18/21 7:00 AM

Nasdaq : DCPH

Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10 th Annual Global Healthcare Conference on February 25, 2021 at 4:20 PM ET. The conference will be held in a virtual

RHEA-AI

neutral

02/09/21 4:01 PM

Nasdaq : DCPH

Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2020, and provided a business update."We made significant progress in 2020 with the successful launch of QINLOCK, completing enrollment in the Phase 3 INTRIGUE study

RHEA-AI

positive

02/04/21 7:00 AM

Nasdaq : DCPH

Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 11, 2021 at 11:00 AM ET. The conference will be held in a virtual

RHEA-AI

neutral

02/02/21 7:00 AM

Nasdaq : DCPH

Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, February 9, 2021.In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 4:30 PM ET

RHEA-AI

neutral

01/11/21 7:00 AM

Nasdaq : DCPH

Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2021 milestones in conjunction with its presentation at the 39 th Annual J.P.

RHEA-AI

very positive

01/05/21 7:23 AM

Nasdaq : DCPH

Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 AM ET.A live webcast of the event will be available on the "Events and

RHEA-AI

neutral

11/30/20 7:00 AM

Nasdaq : DCPH

Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK(R) (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and safety of QINLOCK in patients with second-line gastrointestinal stromal tumor (GIST). QINLOCK, the Company's switch-control tyrosine kinase inhibitor, is currently approved in the U.S., Canada, and Australia for patients with fourth-line GIST. "We are pleased to announce the completion of target

RHEA-AI

neutral